These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24806515)

  • 1. Comparative assessments of crucial factors for a functional ligand-targeted nanocarrier.
    Hossen MN; Kajimoto K; Tatsumi R; Hyodo M; Harashima H
    J Drug Target; 2014 Aug; 22(7):600-9. PubMed ID: 24806515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Harashima H
    J Control Release; 2012 Oct; 163(2):101-10. PubMed ID: 22982237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
    J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.
    Hossen N; Kajimoto K; Akita H; Hyodo M; Harashima H
    J Control Release; 2013 Oct; 171(2):104-12. PubMed ID: 23871959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature.
    Sakurai Y; Kajimoto K; Harashima H
    Biomater Sci; 2015 Sep; 3(9):1253-65. PubMed ID: 26261854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
    Ishitsuka T; Akita H; Harashima H
    J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
    Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
    Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic assessment of cytochrome C for the prevention of obesity through endothelial cell-targeted nanoparticulate system.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
    Mol Ther; 2013 Mar; 21(3):533-41. PubMed ID: 23295953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in an active and passive targeting to tumor and adipose tissues.
    Sakurai Y; Kajimoto K; Hatakeyama H; Harashima H
    Expert Opin Drug Deliv; 2015 Jan; 12(1):41-52. PubMed ID: 25376864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.
    Zhang Z; Chen J; Ding L; Jin H; Lovell JF; Corbin IR; Cao W; Lo PC; Yang M; Tsao MS; Luo Q; Zheng G
    Small; 2010 Feb; 6(3):430-7. PubMed ID: 19957284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferrin- and folate-modified, double-targeted nanocarriers for gene delivery.
    Jing F; Li D; Xu W; Liu Y; Wang K; Sui Z
    Pharm Biol; 2014 May; 52(5):570-4. PubMed ID: 24256214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.
    Wang T; Kulkarni N; Bedi D; D'Souza GG; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
    J Drug Target; 2011 Sep; 19(8):597-605. PubMed ID: 21275826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of obesity by targeted ablation of adipose tissue.
    Kolonin MG; Saha PK; Chan L; Pasqualini R; Arap W
    Nat Med; 2004 Jun; 10(6):625-32. PubMed ID: 15133506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation.
    Zhao P; Wang H; Yu M; Liao Z; Wang X; Zhang F; Ji W; Wu B; Han J; Zhang H; Wang H; Chang J; Niu R
    Eur J Pharm Biopharm; 2012 Jun; 81(2):248-56. PubMed ID: 22446630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
    Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
    Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted SAINT-O-Somes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells.
    Adrian JE; Morselt HW; Süss R; Barnert S; Kok JW; Asgeirsdóttir SA; Ruiters MH; Molema G; Kamps JA
    J Control Release; 2010 Jun; 144(3):341-9. PubMed ID: 20226822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake.
    Takara K; Hatakeyama H; Ohga N; Hida K; Harashima H
    Int J Pharm; 2010 Aug; 396(1-2):143-8. PubMed ID: 20457236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
    Ara MN; Matsuda T; Hyodo M; Sakurai Y; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2014 Aug; 35(25):7110-20. PubMed ID: 24875764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative control of active targeting of nanocarriers to tumor cells through optimization of folate ligand density.
    Tang Z; Li D; Sun H; Guo X; Chen Y; Zhou S
    Biomaterials; 2014 Sep; 35(27):8015-27. PubMed ID: 24947231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus.
    Elsaid N; Somavarapu S; Jackson TL
    Exp Eye Res; 2014 Apr; 121():121-9. PubMed ID: 24530465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.